MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results

Go back to MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results

Macrogenics (MGNX) Misses Q2 EPS by 20c

July 29, 2021 4:49 PM EDT

Macrogenics (NASDAQ: MGNX) reported Q2 EPS of ($0.66), $0.20 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $27.2 million versus the consensus estimate of $30.03 million.

For earnings history and earnings-related data on Macrogenics (MGNX) click here.

... More